Differences in terms of progression-free survival (PFS) and overall survival (OS) in patients treated with first-line sorafenib, sunitinib, and pazopanib for late relapsing (>5 years) renal cell carcinoma
| Image |  |
|---|---|
| Description | |
| Author/s |
author: Umberto Basso Rossana Berardi Roberto Iacovelli Ugo De Giorgi Daniele Santini |
| Publication date | February 2014 |
| Language | English |
| Country of origin | |
| Wikipedia link | |
| Copyright status | |
| Missing/wrong data? | Edit Wikidata item |